Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Psoriatic Arthritis (IMPACT 2)
NCT00051623Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2003
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Infliximab 5 mg/kg with Placebo (2 arms). Primary endpoints: American College of Rheumatology 20 Response at 14 weeks and Change in Total Radiographic Scores of Hands and Feet at 24 weeks. Started May 2003; status: completed.
02
Drugs
infliximab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00051623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051623.